Mitsubishi UFJ Asset Management’s Denali Therapeutics DNLI Stock Holding History

Mitsubishi UFJ Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$25.7K	Hold	1,001	–	–	﹤0.01%	1278
2026 Q1	$19.2K	Hold	1,001	–	–	﹤0.01%	1271
2025 Q4	$16.3K	Hold	1,001	–	–	﹤0.01%	1275
2025 Q3	$14.5K	Hold	1,001	–	–	﹤0.01%	1272
2025 Q2	$14K	Hold	1,001	–	–	﹤0.01%	1277
2025 Q1	$13.6K	Hold	1,001	–	–	﹤0.01%	1242
2024 Q4	$21.3K	Hold	1,001	–	–	﹤0.01%	1151
2024 Q3	$29.2K	Hold	1,001	–	–	﹤0.01%	1072
2024 Q2	$23.2K	Buy	1,001 +856	+590%	+$16.4K	﹤0.01%	1077
2024 Q1	$2.98K	Hold	145	–	–	﹤0.01%	1528
2023 Q4	$2.95K	Hold	145	–	–	﹤0.01%	1528
2023 Q3	$2.99K	Buy	+145	New	+$3.68K	﹤0.01%	1494
2018 Q4	–	Sell	-1,830	Closed	-$40K	–	924
2018 Q3	$40K	Sell	1,830 -125	-6%	-$2.07K	﹤0.01%	917
2018 Q2	$30K	Sell	1,955 -133	-6%	-$2.51K	﹤0.01%	846
2018 Q1	$41K	Sell	2,088 -62	-3%	-$1.27K	﹤0.01%	835
2017 Q4	$36K	Buy	+2,150	New	+$38.6K	﹤0.01%	824

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mitsubishi UFJ Asset Management's DNLI Position: Q2 2026 in Review

Mitsubishi UFJ Asset Management held its Denali Therapeutics (DNLI) position steady in Q2 2026 at 1,001 shares worth $25.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1278.

Mitsubishi UFJ Asset Management first reported a position in DNLI in Q4 2017 and has held it in 16 quarters since. The position peaked at $41K in Q1 2018. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Mitsubishi UFJ Asset Management held 1,001 shares of Denali Therapeutics worth $25.7K as of Q2 2026.
Mitsubishi UFJ Asset Management left its Denali Therapeutics share count unchanged in Q2 2026.
Denali Therapeutics made up ﹤0.01% of Mitsubishi UFJ Asset Management's portfolio in Q2 2026, its #1278 holding.
Mitsubishi UFJ Asset Management first reported a position in Denali Therapeutics in Q4 2017 and has held it in 16 quarters since.
Mitsubishi UFJ Asset Management's Denali Therapeutics position peaked at $41K in Q1 2018.
292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Mitsubishi UFJ Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.